Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide.

× No keyword cloud information.

9 in total

1. Best candidates for dopamine agonist withdrawal in patients with prolactinomas.

Authors: Myoung Jin Ji; Jung Hee Kim; Ji Hyun Lee; Jung Hyun Lee; Yong Hwy Kim; Sun Ha Paek; Chan Soo Shin; Seong Yeon Kim
Journal: Pituitary Date: 2017-10 Impact factor: 4.107

2. TRH raises cytosolic Ca2+ in human adenomatous lactotrophs.

Authors: A Spada; F Reza-Elahi; A Lania
Journal: J Endocrinol Invest Date: 1990-01 Impact factor: 4.256

3. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine.

Authors: A Spada; M Bassetti; E Martino; G Giannattasio; P Beck-Peccoz; A Sartorio; L Vallar; L Baschieri; A Pinchera; G Faglia
Journal: J Endocrinol Invest Date: 1985-06 Impact factor: 4.256

Review 4. Medical therapy of pituitary adenomas: effects on tumor shrinkage.

Authors: Annamaria Colao; Rosario Pivonello; Carolina Di Somma; Silvia Savastano; Ludovica F S Grasso; Gaetano Lombardi
Journal: Rev Endocr Metab Disord Date: 2009-06 Impact factor: 6.514

5. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.

Authors: E Ciccarelli; E Ghigo; E Mazza; M Andreis; F Massara; I Lancranjan; F Camanni
Journal: J Endocrinol Invest Date: 1987-04 Impact factor: 4.256

Review 6. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Authors: C P Rains; H M Bryson; A Fitton
Journal: Drugs Date: 1995-02 Impact factor: 9.546

In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide.

1. Best candidates for dopamine agonist withdrawal in patients with prolactinomas.

2. TRH raises cytosolic Ca2+ in human adenomatous lactotrophs.

3. In vitro studies on TSH secretion and adenylate cyclase activity in a human TSH-secreting pituitary adenoma. Effects of somatostatin and dopamine.

Review 4. Medical therapy of pituitary adenomas: effects on tumor shrinkage.

5. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia.

Review 6. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.

Review 7. The role of vasoactive intestinal polypeptide (VIP) as a hypothalamic neurohormone.

Review 8. Diagnosis and drug therapy of prolactinoma.

9. Abnormal transduction of dopamine signal in human nonfunctioning pituitary adenomas.